Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo Begins Shipment of Generic MIACALCIN? (calcitonin salmon) Injection

11/18/2021 | 07:30am EST

Endo International plc announced that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par's calcitonin salmon injection is AP-rated to Viatris' MIACALCIN? and is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required. Calcitonin salmon injection is also used to treat postmenopausal osteoporosis in women greater than 5 years postmenopause and to treat symptomatic Paget's disease of bone when alternative treatments are not suitable for these conditions. According to IQVIA data, U.S. sales of calcitonin salmon injection were approximately $170 million for the 12 months ended September 2021. MIACALCIN? is a registered trademark of Novartis AG, licensed to the Viatris Companies.


ę S&P Capital IQ 2021
All news about ENDO INTERNATIONAL PLC
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/18Endo International Reaches Settlement With Florida Over Opioid Claims
MT
01/18Drugmaker Endo signs $65 million opioid settlement with Florida
RE
01/18Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
PR
01/17Paladin Labs Announces the Launch of Xydalba« (dalbavancin for injection) in Canada
AQ
01/13Endo Announces Publication of New AVEED« (testosterone undecanoate) Data in Peer-Review..
PR
01/13Endo Announces Publication of New AVEED« (testosterone undecanoate) Data in Peer-Review..
CI
01/11Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients, Watching Ed..
AQ
01/11ENDO INTERNATIONAL : at J.P. Morgan Healthcare Conference
PU
01/11ENDO INTERNATIONAL PLC : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 940 M - -
Net income 2021 10,2 M - -
Net Debt 2021 6 712 M - -
P/E ratio 2021 2,41x
Yield 2021 -
Capitalization 776 M 776 M -
EV / Sales 2021 2,55x
EV / Sales 2022 2,57x
Nbr of Employees 3 397
Free-Float -
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 3,32 $
Average target price 6,17 $
Spread / Average Target 85,7%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations